Compare LSTA & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | SCNX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.8M |
| IPO Year | N/A | 2020 |
| Metric | LSTA | SCNX |
|---|---|---|
| Price | $1.98 | $0.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000.00 | $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 207.88 |
| 52 Week Low | $1.81 | $0.46 |
| 52 Week High | $4.20 | $7.69 |
| Indicator | LSTA | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 41.93 |
| Support Level | $2.00 | $0.49 |
| Resistance Level | $2.17 | $0.60 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 8.00 | 6.82 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.